Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Inclusion Criteria:

• Age ≥ 18 years.
• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2
• Life expectancy ≥ 3 months.
• Patients previously diagnosed with multiple myeloma
• Patients must have relapsed or relapsed and refractory multiple myeloma (MM) after atleast three but not more than six prior therapeutic regimens for MM, includinginduction therapy and stem cell transplant in candidate patients, which will beconsidered as only one regimen.
• Patients must have received previous bortezomib-containing and lenalidomide-containingregimens (or thalidomide where lenalidomide is not available)
• Women must have a negative serum pregnancy test
• Voluntarily signed and dated written informed consent

Exclusion Criteria:

• Concomitant diseases/conditions
• Women who are pregnant or breast feeding.
• Concomitant medications that include corticosteroids, chemotherapy, or other therapythat is or may be active against MM
• Known hypersensitivity to any involved study drug or any of its formulation components